Investors

News Releases

Date Title  
Toggle Summary Pozen Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US $350 Million Capital Commitment from Deerfield-Led Syndicate toFund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products MILTON, ONTARIO -- (Marketwired) -- 06/17/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition,
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela®, Proferrin® and 13 Additional Products MILTON, ONTARIO--(Marketwired - June 17, 2015) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the
Toggle Summary POZEN Announces Key Leadership Additions
Three New Executives, Each Bring Decades of Experience Working at High Growth Pharmaceutical Companies New Executives Will Also Serve on Leadership Team of Aralez Pharmaceuticals , Following Completion of Merger with Tribute CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 22, 2015-- POZEN Inc.
Toggle Summary POZEN Appoints Scott Charles Senior Vice President of Finance
Charles to Serve as Chief Financial Officer of Aralez Following Completion of Merger with Tribute Pharmaceuticals CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced
Toggle Summary POZEN Announces August 10th Webcast of Second Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015 , before the market opens. The announcement will be followed by a live webcast at 2:00 p.m.
Toggle Summary POZEN Reports Second Quarter 2015 Results
-Strategic Merger with Tribute Pharmaceuticals Expected to Close in the 4Q 2015- -Commercialization Plans for YOSPRALA TM Underway- CHAPEL HILL, N.C. --(BUSINESS WIRE)--Aug. 10, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced results for the second quarter ended June 30, 2015 .
Toggle Summary Tribute Pharmaceuticals Announces Second Quarter 2015 Results
Revenue Up 59%, Gross Profit Up 101% over Comparative Period MILTON, ONTARIO -- (Marketwired) -- 08/17/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing,
Toggle Summary POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Sep. 14, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced that James P. Tursi, M.D. will be appointed Chief Medical Officer of POZEN , effective October 1, 2015 . Dr. Tursi will report to Adrian Adams , Chief Executive Officer of POZEN , and will be responsible

Copyright West LLC. Minimum 15 minutes delayed.